patrick.net
An Antidote to Corporate Media
1,249,612 comments by 14,902 users - FuckTheMainstreamMedia, RWSGFY, Tenpoundbass online now
COVID-19 mRNA transfection reagents - a terrible bet.
invite response
2023 Feb 3, 4:03pm 485 views 2 comments
Comments 1 - 2 of 2 Search these comments
1
Patrick
2023 Feb 3, 4:27pm
Patrick
2023 Feb 3, 4:27pm
Al_Sharpton_for_President says
@Al_Sharpton_for_President
That should be about 1/1,000.
But even that is too low, unless it's per dose. About 1 in 800 die from the vaxx within 5 or 6 months of getting it, with deaths skewed younger rather than older.
I say this based on the est. 275,000 dead in the US from the vaxx, and the 100,000 in Germany. 1 in 800 dead is also the estimate of some Indian doctor associated with the BMJ in Britain.
10.1 per 10,000 vaccinated. (1/10,000)
@Al_Sharpton_for_President
That should be about 1/1,000.
But even that is too low, unless it's per dose. About 1 in 800 die from the vaxx within 5 or 6 months of getting it, with deaths skewed younger rather than older.
I say this based on the est. 275,000 dead in the US from the vaxx, and the 100,000 in Germany. 1 in 800 dead is also the estimate of some Indian doctor associated with the BMJ in Britain.
2
Ceffer
2023 Feb 3, 4:29pm
Ceffer
2023 Feb 3, 4:29pm
Al_Sharpton_for_President says
You're just saying that because you don't appreciate all the wonderful protection the Globalists have offered us.
COVID-19 mRNA transfection reagents - a terrible bet.
You're just saying that because you don't appreciate all the wonderful protection the Globalists have offered us.
Moderna mRNA COVID-19 vaccines, associated with an excess risk of serious adverse events of special interest, 15.1 per 10,000 vaccinated. (1/650)
Combined, Pfizer and Moderna COVID-199 vaccines, associated with an excess risk of serious adverse events of special interest, 1/800.
UK Health Security Agency (UKHSA):
16-19 years, autumn booster:
risk of COVID-19 hospitalization: 1/73,500. (73,500 individuals receive the booster to prevent 1 hospitalization.) 92 of the boosted experience a serious adverse event of special interest. Risk/benefit: 92/1.
risk of COVID-19 severe hospitalization: 1/185,100. (185,100 individuals receive the booster to prevent 1 severe hospitalization.) 231 of the boosted experience a serious adverse event of special interest. Risk/benefit: 231/1.
20-29 years, autumn booster, no risk group:
risk of COVID-19 hospitalization: 1/169,200. (169,200 individuals receive the booster to prevent 1 hospitalization.) 211 of the boosted experience a serious adverse event of special interest. Risk/benefit: 211/1.
risk of COVID-19 severe hospitalization: 1/706,500. (706,500 individuals receeive the booster to prevent 1 severe hospitalization.) 883 of the boosted experience a serious adverse event of special interest. Risk/benefit: 883/1.
20-29 years, autumn booster, risk group:
risk of COVID-19 hospitalization: 1/7,500. (7,500 individuals receive the booster to prevent 1 hospitalization.) 9 of the boosted experience a serious adverse event of special interest. Risk/benefit: 9/1.
risk of COVID-19 severe hospitalization: 1/59,500. (59,500 individuals receive the booster to prevent i severe hospitalization.) 74 of the boosted experience a serious adverse event of special interest. Risk/benefit: 74/1.
https://rumble.com/v288s9y-pfizer-admit-adverse-vaccine-reactions.html
Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults.
https://pubmed.ncbi.nlm.nih.gov/36055877/